Inogen, Inc (INGN) News
Filter INGN News Items
INGN News Results
|Loading, please wait...|
INGN News Highlights
- For INGN, its 30 day story count is now at 9.
- Over the past 7 days, the trend for INGN's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
Latest INGN News From Around the Web
Below are the latest news stories about INOGEN INC that investors may wish to consider to help them evaluate INGN as an investment opportunity.
The shares of Inogen Inc. (INGN) fell in the morning hours Tuesday after William Blair downgraded it to Market Perform from Outperform, citing macro headwinds. Read the full story here.
Inogen's (INGN) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its product sales.
GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced unaudited preliminary revenue results for the fourth quarter and the full year ended December 31, 2022. The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2022 to be in the range of $87.5 million to $88.5 million, representing year-over-year growth of 14.5% to 15.8%. Full year 2022 to
Inogen (INGN) estimates Q4 total revenue to be in the range of $87.5M to $88.5M, representing Y/Y growth of 14.5% to 15.8%, vs consensus of $89.48M
GOLETA, Calif., January 10, 2023--Inogen Achieves Regulatory Milestones to Support Current and Future Products
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference. Nabil Shabshab, President and Chief Executive Officer, is scheduled to present on Wednesday, January 11, 2023, at 10:30 a.m. Pacific Time. A
Shockwave Medical (SWAV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Structural, supply chain headwinds remain in situ, especially compressing divisional sales growth in Q3. Click here to read my analysis of Inogen stock.
GOLETA, Calif.--(BUSINESS WIRE)--Inogen to Present at Upcoming Investor Conferences in November 2022